Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

  • June 2025 quarter CPI no roadblock to August RBA rate cut
    June 2025 quarter CPI no roadblock to August RBA rate cut
    • News

BlinkLab Kicks Off U.S. Autism Diagnostic Study with First Patient Tested

  • In News
  • March 12, 2025
  • Gracen Moore
BlinkLab Kicks Off U.S. Autism Diagnostic Study with First Patient Tested

Addressing Critical Gaps in Autism Diagnosis

Autism spectrum disorder (ASD) affects millions of children worldwide, yet early diagnosis remains a major challenge. Despite recommendations from the American Academy of Paediatrics (AAP) for autism screening at 18 and 24 months, many children experience delays in diagnosis, missing the crucial window for early intervention.

BlinkLab Limited (ASX:BB1) is working to bridge this gap with its AI-powered, smartphone-based diagnostic tool, BlinkLab Dx1. The company has now officially launched its pivotal U.S. clinical trial, aiming to validate the technology as a critical aid for early autism detection.

CEO Highlights the Significance of This Milestone

Dr. Henk-Jan Boele, Cofounder and CEO of BlinkLab, described the trial’s commencement as a defining moment for the company.

“Launching our U.S. trial marks a very special and important moment for BlinkLab,” Dr. Boele said. “Our mission has always been to connect fundamental neuroscience with clinical practice through accessible technology, thereby enhancing autism diagnostic evaluations and enabling early intervention for children.”

The first child has now been tested at PriMED Clinical Research LLC in Dayton, Ohio, marking the beginning of what will be the largest digital diagnostic trial for autism in the U.S.

Aiming for a Faster, More Accessible Autism Diagnosis

The BlinkLab Dx1 test is designed to provide healthcare providers with a rapid and reliable diagnostic aid. By using AI-driven assessments via smartphones, the technology aims to reduce the time between initial concerns and formal diagnosis.

PriMED Clinical Research, a research-focused arm of PriMED Physicians, is one of the first two clinical sites selected for the initial phase of the trial. North Shore Pediatric Therapy will also participate in the study.

“After extensive app and portal development, stimulus refinement, and testing in hundreds of children, we are very confident in our FDA study’s potential,” Dr. Boele said. “Early diagnosis is life-changing, and BlinkLab is dedicated to empowering families and healthcare providers with AI-driven tools for accurate, accessible, and timely autism assessments.”

Study Progress and Regulatory Pathway

The study will first enrol 100 participants, with initial data expected to be released in Q3 CY2025. Following this phase, the trial will expand significantly, with plans to enrol an additional 750 to 900 children.

The results will form the foundation for BlinkLab’s submission for FDA 510(k) clearance, which is anticipated at the end of CY2025. Regulatory approval will allow the company to enter the U.S. market and provide clinicians with a cutting-edge tool for early autism detection.

Clinical Research Team Backs the Technology

Crystal Jackson, Certified Clinical Research Coordinator and Site Manager for PriMED Clinical Research (PCR) emphasised the significance of this study for both the medical field and affected families.

“Dr. Rogelio Amisola, Principal Investigator, and PCR’s team of dedicated investigators & coordinators are thrilled to be the first U.S. site to screen participants in this monumental milestone for BlinkLab,” Jackson said. “We are hopeful our quality of data will assist BlinkLab Dx1 in advancing AI technology to support medical professionals in the early detection of autism—bringing innovation and hope to families everywhere.”

A Game-Changer for Early Intervention

BlinkLab’s work is set to revolutionise how autism and other neurodevelopmental disorders are diagnosed. With its AI-powered solution, the company is addressing a major gap in the healthcare system, ensuring children receive timely support during crucial developmental stages.

As the study progresses, all eyes will be on the upcoming data release in Q3 2025, which could further solidify BlinkLab’s position as a leader in digital diagnostics. With FDA clearance on the horizon, the company is on track to deliver a breakthrough in autism detection that could transform the lives of countless families.

  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Stakk Secures T-Mobile Contract to Power Super App Expansion - September 30, 2025
  • Medibank Backs Emyria with Landmark Depression Care Deal - September 22, 2025
  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI - September 19, 2025
  •  
  •  
  •  
  •  
  • ASX:BB1
  • News

Leave a Comment

You must be logged in to post a comment.

1 Comment

  • Shraddha13
    March 12, 2025, 9:20 pm

    Thank you for sharing! To explore further
    https://www.360iresearch.com/library/intelligence/autism-spectrum-disorders

    Reply
  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Stakk Secures T-Mobile Contract to Power Super App Expansion - September 30, 2025
  • Medibank Backs Emyria with Landmark Depression Care Deal - September 22, 2025
  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI - September 19, 2025

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Stakk Secures T-Mobile Contract to Power Super App Expansion - September 30, 2025
  • Medibank Backs Emyria with Landmark Depression Care Deal - September 22, 2025
  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI - September 19, 2025
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.